Connect with us

Media OutReach

Uni-Bio Science Group Embarks on New Strategy and Launches New Website, Advancing Towards Becoming a Global Leader in Regenerative Medicine

Published

on

HONG KONG SAR – EQS Newswire – 24 November 2025 – Uni-Bio Science Group Limited (“Uni-Bio” or “the Group”) recently announced its official entry into a new phase of strategic development. Over the past few years, amidst profound biopharmaceutical industry transformation and multiple market challenges, the Group has consistently adhered to stable operations as its core focus, building financial resilience and commercialization capabilities. It has not only achieved sustained revenue growth and healthy cash flow, but also successfully advanced its blockbuster product – Bogutai® (Teriparatide Injection) – which was approved in China in January 2024, filling a crucial gap in its osteoporosis treatment portfolio. The Group is currently actively advancing the US FDA application for Uni-PTH, expected to be approved in 2027, and has entered a strategic collaboration with Kexing for six international markets, marking a key step in its global strategy.

Building on these solid achievements, Uni-Bio has decided to shift its strategic focus comprehensively from “Stable Growth” to “Innovation-Driven.” Leveraging next-generation synthetic biology and complex peptides as technological engines and focusing on the forefront of regenerative medicine, the Group is initiating a strategic leap from an “Excellent Pharmaceutical Company” to a “Global Leader in Regenerative Medicine.”

1. New Corporate Vision and Mission: Anchoring the Future of Regenerative Medicine

Alongside this strategic upgrade, Uni-Bio announced its new corporate vision and mission, demonstrating not only its ambition to be rooted in China with a global outlook but also its deep consideration for the future of human health.

Vision:
” To Be the Global Leader in Regenerative Medicine, Redefining How Science Restores and Extends Human Life.”

Mission:
“Powering the Advancement of Regenerative Medicine with Next-Generation Synthetic Biology and Complex Peptide Innovation.”

2. Strategic Focus Areas: Comprehensive Breakthroughs in Four Regenerative Medicine Fields

Capitalizing on its profound expertise in synthetic biology and peptide technology, Uni-Bio is building a transformative pipeline covering four key areas – Muscular-Skeletal Regeneration, Skin Regeneration, Ocular Regeneration, and ENT (Ear, Nose, and Throat) Regeneration. These areas address core unmet clinical needs and promote the transition of regenerative medicine from the laboratory to broad clinical application through the deep integration of cutting-edge technologies.

(1) Muscular-Skeletal Regeneration

Focus on developing osteoporosis treatment and repair products, combined with stem cell technology, to drive breakthroughs in the diagnosis and treatment of bone, cartilage, and muscle injuries and degenerative diseases. Specific projects include:

  • UB107 (BMP-2 Biomedical Material): A key growth factor in regenerative medicine, BMP-2 can be widely used clinically for bone defect reconstruction and spinal fusion surgery. It is expected to be approved for market launch in 2028, further consolidating Uni-Bio’s market share and position in the field of bone regeneration.
  • UB106 (Novel Target Antibody for Obesity): Addressing the limitations of current obesity treatments, UB106 directly targets issues such as muscle loss, frequent dosing, gastrointestinal side effects, and pancreatitis. It is expected to be approved as early as 2030, offering a new treatment option for patients with obesity.

(2) Skin Regeneration

Leveraging advanced growth factor technologies and innovative delivery systems to provide precise repair solutions for burns, scalds, and hard-to-heal wounds, while also offering comprehensive solutions in the medical aesthetics field. Recently approved products include:

  • GeneTime® (Human Epidermal Growth Factor Derivative for External Use, Liquid, 30ml large specification): Approved by the NMPA in November 2025 (Approval No.: 國藥准字 S20258020). The approval of this new specification will significantly enhance GeneTime’s clinical applicability and market coverage, meeting the diverse medication needs of medical institutions at all levels and the end market.
  • Gene Queens® (Triple Protein Repair &Balance Ampoule): This product was approved recently, further completing the Group’s comprehensive “Drug & Medical Device & Cosmetic” skincare solution portfolio.

(3) Ocular Regeneration

Uni-Bio is actively exploring the field of ocular regeneration, utilizing advanced strategies such as hEGF and anti-VEGF, to remodel ocular surface and retinal function. Through active collaborations with leading international companies and top domestic universities, the Group is advancing the R&D of potential drugs for diseases, such as age-related macular degeneration. The Group’s mission is to accelerate the translation of cutting-edge technologies into clinical applications, thereby bringing new hope to patients with ocular diseases.

(4) ENT Regeneration

Centered on neurotrophic factor technology, Uni-Bio is pioneering innovative R&D in ENT regeneration, The Group is exploring novel solutions for reversing hearing loss and rebuilding olfactory function, driving new breakthroughs in the restoration of ENT organ function.

3. Reiterating the Firm Commitment to Innovation and Collaboration

Entering this new phase of strategic development, Uni-Bio is infusing the pioneering spirit of its startup days into a higher-level mission. This transformation marks the Group’s official evolution from a biopharmaceutical company with strong commercialization capabilities to a clinical-value-oriented leader in regenerative medicine driven by frontier science.

Consequently, Uni-Bio will more openly embrace collaboration across industry-academia-research-medicine, international technology partnerships, and co-building a capital ecosystem. It will actively seek deep synergies with top global research institutions, clinical experts, industry partners, and investors. To communicate this strategic vision and R&D progress more transparently and efficiently, Uni-Bio has simultaneously launched a new Chinese and English official website. The new website systematically presents the Company’s pipeline across the four regenerative medicine fields, its technology platforms, and milestone achievements, while also strengthening investor relations (IR) and scientific collaboration access points, aiming to become a vital bridge connecting global partners.

We sincerely invite partners, investors, research colleagues, and friends from all sectors interested in the future of regenerative medicine to visit Uni-Bio’s new website, delve deeper into our scientific story, and join us in participating and witnessing this journey of reshaping life through innovation.

Uni-Bio Chinese Website: https://www.uni-bioscience.com/
Uni-Bio English Website: https://www.uni-bioscience.com/enHashtag: #UniBioScienceGroup

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001(Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life.

Media OutReach

OOm Institute Calls for AI Fluency to Close Human Critical Thinking Gap

Published

on

SINGAPORE – Media OutReach Newswire – 10 June 2026 – OOm Institute, a Singapore-based AI and digital skills training provider, is calling for greater AI fluency as businesses adopt Generative AI and concerns grow over declining critical thinking and verification skills.

The rapid adoption of AI tools without sufficient verification, contextual understanding, or critical oversight is contributing to a growing “Human Critical Thinking Gap”.

Recent research from Professors Rick Dakan and Joseph Feller also corroborates this; only 8.7% of participants consistently verified high-stakes AI-generated claims before accepting them.

Beyond the Prompt: The Human-Centric Shift

While prompt engineering remains a foundational skill for today’s workforce, OOm Institute suggests the discipline must evolve beyond simple input mechanics.

“We are entering a false competence trap,” says Ian Cheow, CEO at OOm Institute. “People are learning how to prompt, but they aren’t learning how to make the right decisions. If you cannot spot when an AI’s logic fails, you aren’t using a tool, you are delegating your intelligence.”

The Warning: If You Let AI Think for You, You “De-skill”

Professionals who rely heavily on AI without developing critical evaluation skills risk “de-skilling”, where domain expertise erodes over time due to over-dependence on automated systems.

The concept of AI Fluency is built around three core capabilities:

  • Decision to Correct: The ability to determine when AI-generated output is sufficient and when it poses a risk that requires human revision or rejection.
  • Contextual Sovereignty: Ensuring human oversight remains central so AI outputs align with Singapore’s cultural, commercial, and ethical contexts.
  • Critical Inquiry: Moving beyond prompting to actively question assumptions, logic, accuracy, and completeness in AI-generated responses.

Real-World Practice vs Theory

As AI tools evolve rapidly, practitioners argue that effective AI capability cannot rely solely on static classroom theory. Real-world usage often involves changing workflows, unpredictable outputs, and context-specific decision-making that require continuous practical application and human judgment.

Maintaining AI fluency increasingly requires learning from practitioners actively applying these tools in commercial environments.

“At OOm Institute, our focus is on building practical decision-making in AI usage,” Mr Cheow added. “Our goal is to help professionals use AI with stronger critical thinking, clearer accountability, and practical business understanding.”
Hashtag: #aicourse #wsqaicourse #aisingapore #aifluency #aiskills




The issuer is solely responsible for the content of this announcement.

OOm Institute

OOm Institute is a WSQ course provider in Singapore, supporting workforce upskilling in AI, Digital Marketing, and Soft Skills, backed by expert trainers and over 20 years of digital expertise. They deliver industry-oriented learning programmes designed to help organisations apply digital tools effectively in real-world business environments.

Continue Reading

Media OutReach

Suanova, a Subsidiary of Yeebo, Signs Comprehensive Strategic Cooperation Agreement with InfiX.ai

Published

on

Advancing Deployment of Training and Inference Integrated AI Platforms in Healthcare Applications, Powered by Domestic High-Density Computing Infrastructure

HONG KONG SAR – Media OutReach Newswire – 10 June 2026 – Yeebo (International Holdings) Limited (“Yeebo”; Stock Code: 00259.HK, together with its subsidiaries, the “Group”) is pleased to announce that its wholly-owned subsidiary, Suanova Technology Limited (“Suanova”), has entered into a comprehensive strategic cooperation agreement with InfiX.ai, a global leader in enterprise-grade generative AI (GenAI) infrastructure solutions. Leveraging Suanova’s Shanghai Cube, a domestically developed high-density computing infrastructure, the two parties will jointly advance the deployment of training and inference integrated AI platforms with continuous self-learning capabilities in healthcare applicatoins. As part of this collaboration, Suanova will contribute its expertise in domestic computing infrastructure by providing the core computing power and foundational support.

With healthcare as the initial focus, the two parties have already collaborated with leading medical institutions to conduct clinical validation in areas such as cancer GenAI, foundational medical Large Language Models (LLMs) and personalized cancer treatment planning.

Building Integrated Infrastructure for Medical AI with Shanghai Cube as the Foundation

The training and inference integrated AI platforms deployed under this collaboration are powered by Shanghai Cube, combined with InfiX.ai’s training, inference and multimodal AI capabilities. This integration delivers a truly unified hardware-software infrastructure tailored for medical AI applications.

Shanghai Cube, developed with the participation of Suanova, was among the earliest of its kind in China and is currently the highest-density domestically developed GPU supernode product. It adopts a high-density deployment architecture featuring 128 GPUs per rack with liquid cooling, enabling compact and efficient deployment of large-scale computing clusters. Shanghai Cube integrates a range of domestically produced core components, including liquid-cooling systems, high-performance parallel storage systems, retimers and motherboard capacitors. It provides a one-stop, highly efficient solution for the large-scale deployment of domestic computing systems and models.

Partnering with InfiX.ai to Build Enterprise-Grade AI Infrastructure

InfiX.ai is a research-driven AI infrastructure company serving global markets, with capabilities spanning IaaS, PaaS and MaaS. The company is building a Decentralized Co-GenAI Network that connects computing power, models, platforms and intelligent applications, with the aim of helping enterprises and organizations train, deploy and own their domain-specific AI based on proprietary data, expertise and business workflows.

InfiX.ai brings together world-class talent in AI research and industry deployment. The company is led by its Founder and Chief Scientist, Prof. Hongxia Yang, with Co-Founder and Vice President Haiqing Chen and Chief AI Architect Jianmin Wu forming the core management and technology team. Prof. Yang is also a Chair Professor at The Hong Kong Polytechnic University and is a globally recognized leader in artificial intelligence, with extensive experience spanning both academia and industry. She previously served as Head of LLMs in the at ByteDance (U.S.), AI Scientist and Director at Alibaba Group, Chief Data Scientist at Yahoo!, and Research Staff Member at IBM T.J. Watson Research Center. Prof. Yang has published more than 150 papers and holds over 50 patents. She has also received numerous international honors, including the WAIC SAIL Award, the National Scientific and Technological Progress Award, and recognition as one of the AI 2000 Most Influential Scholars worldwide.

By integrating InfiX.ai’s training and inference algorithms with Suanova’s high-performance computing platform, the solution significantly reduces memory usage and computing resource requirements. This enables higher throughput and supports training and deployment of larger-scale models under equivalent hardware configurations. The system is also capable of continuously capturing data for incremental training, integrating user feedback for fine-tuning and reinforcement learning, thereby ensuring that model performance evolves alongside changing business needs. Furthermore, the infrastructure supports local execution of the entire AI workflow – from training and fine-tuning to inference – thereby ensuring data security by design and meeting the stringent security requirements of sectors such as healthcare, finance, and government.

Mr. Daliang Chen, CEO of Suanova, said: “This partnership with InfiX.ai represents an important milestone in Suanova’s expansion into medical AI. Leveraging the Shanghai Cube high-density domestic computing platform, we aim to accelerate the adoption of medical AI in real-world clinical settings. This collaboration not only brings together the complementary strengths of both companies from a technological perspective, but also serves as a key step in advancing the domestic computing ecosystem. Looking ahead, we will continue to work closely with our partners to drive the deep integration of artificial intelligence across diverse industries.”

Hashtag: #Yeebo

The issuer is solely responsible for the content of this announcement.

About Yeebo (International Holdings) Limited

Founded in 1988, Yeebo (International Holdings) Limited is a diversified electronic component company with a well-established presence in the global market. The Company’s core business spans flat panel displays, computing power and capacitors, serving a broad spectrum of industrial and consumer applications. Headquartered in Hong Kong, Yeebo operates its manufacturing operations primarily in the Guangdong and Jiangsu provinces, supporting a global sales network that ensures localized service and support for its international clientele.

In alignment with its long-term strategic vision, Yeebo is leveraging its robust operational foundation to expand into the Artificial Intelligence (“AI”) compute and related sectors. This initiative reflects the Company’s commitment to innovation and technological advancement, with the objective of positioning Yeebo as a leading and influential participant in the rapidly evolving AI industry across mainland China and Hong Kong.

About Suanova Technology Limited

Suanova, under Yeebo, is an innovative technology company focused on delivering independent, efficient, and accessible domestic AI computing services. Its business spans three core areas: computing power and cloud operations, computing technology development and computing industry investment. With branches in Hong Kong and Shanghai, it provides customers with better localized services. It is committed to transforming complex AI infrastructure into simple, efficient, and cost‑effective services through continuous technological innovation, with the goal of becoming a leading “infrastructure operator” in the AI era.

Continue Reading

Media OutReach

KAST chooses Elliptic digital asset decisioning for global AML and sanctions compliance

Published

on

SINGAPORE – Media OutReach Newswire – 10 June 2026 – Elliptic, the global leader in digital asset decisioning, has equipped KAST, the global financial platform built on stablecoin rails , with the blockchain intelligence necessary to strengthen anti-money laundering and sanctions controls across its products and global footprint.

KAST has used Elliptic’s solutions since 2024 to screen wallets and monitor crypto transactions for indicators of financial crime as customers fund and use their KAST accounts. By integrating Elliptic’s blockchain intelligence into its risk and compliance stack, KAST has been able to identify high-risk activity in real-time, reduce exposure to sanctioned or illicit wallets and demonstrate robust controls to regulators and partners.

Founded in July 2024 by former Circle executive Raagulan Pathy, KAST provides USD-denominated accounts, global pay-ins and payouts to more than 170 countries, and a growing suite of consumer and business financial tools built on stablecoin rails rather than legacy settlement networks. With KAST, people can hold, send, and spend instantly while transacting with merchants and ATMs around the world.

Since launch, KAST has scaled to more than one million users and is processing about $5 billion in annualized transaction volume, reflecting the growing adoption of stablecoin-based financial services beyond trading and crypto-native use cases. In March, KAST announced a record $80 million Series A funding round, which is being deployed to expand across North America, Latin America and the Middle East. Elliptic’s analytics help KAST manage risk, applying a consistent, data-driven approach to AML and sanctions screening as the platform scales into new markets.

“Every time customers tap their card, send or receive transactions, they need to trust it’s safe,” said Pathy, Founder & CEO at KAST. “Our users rely on us for institution-grade security everywhere in the world. Elliptic is a key part of that promise. Their blockchain intelligence helps us detect fraud patterns, sanctioned activity and other red flags behind the scenes so that our customers feel safe and secure.”

“As stablecoin financial platforms like KAST reach more users, regulators and partners expect the same standard of financial crime controls that apply in traditional finance,” said James Smith, Co-Founder and Chief Strategy Officer at Elliptic.KAST has been building with compliance in mind from day one. Through this partnership, we are helping to ensure the platform can scale while meeting regulatory expectations for AML and sanctions risk.”

Elliptic’s analytics now underpin KAST’s financial crime controls. Working alongside the platform’s identity, fraud and transaction monitoring solutions, Elliptic supports a consistent, risk-based approach to onboarding, funding and card usage as the platform scales.

Hashtag: #Elliptic

The issuer is solely responsible for the content of this announcement.

About Elliptic

Elliptic is the leader in digital asset decisioning, we have built the most comprehensive platform for efficiently extracting cryptoasset data and intelligence across blockchains with the greatest accuracy.

Our platform’s unrivalled uptime, scalability, depth and breadth of our data and intelligence means exacting organizations choose Elliptic for their compliance, risk management, intelligence operations and blockchain infrastructure needs.

Founded in 2013, Elliptic is headquartered in London with offices in New York, Washington D.C., Miami, Dubai, Hong Kong, Singapore and Tokyo. To learn more, visit and follow us on and .

About KAST

KAST is a stablecoin-powered financial platform that connects digital assets with traditional finance, enabling 1 million+ people to send, receive and convert funds across borders, currencies and payment rails through a single app. The company focuses on helping individuals and businesses earn globally and spend locally by combining instant peer-to-peer transfers with compliant access to local bank payouts in supported markets. Visit www.kast.xyz.

Continue Reading

Trending